Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.37% | -0.57% | 0.69% | -3.31% | -6.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.89% | 10.91% | 14.02% | 13.54% | 12.37% |
| Operating Income | -1.80% | -5.62% | -11.68% | -13.54% | -12.37% |
| Income Before Tax | -1.82% | -4.38% | -12.03% | -11.23% | -10.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.82% | -4.38% | -12.03% | -11.23% | -10.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.82% | -4.38% | -12.03% | -11.23% | -10.43% |
| EBIT | -1.80% | -5.62% | -11.68% | -13.54% | -12.37% |
| EBITDA | -1.47% | -5.21% | -11.46% | -13.49% | -12.49% |
| EPS Basic | 10.57% | 18.15% | 18.42% | 23.47% | 21.23% |
| Normalized Basic EPS | 10.56% | 18.14% | 18.42% | 23.47% | 21.23% |
| EPS Diluted | 10.56% | 17.68% | 17.98% | 23.26% | 21.02% |
| Normalized Diluted EPS | 10.56% | 18.14% | 18.42% | 23.47% | 21.23% |
| Average Basic Shares Outstanding | 12.73% | 25.71% | 35.40% | 45.01% | 41.57% |
| Average Diluted Shares Outstanding | 12.73% | 25.71% | 35.40% | 45.01% | 41.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |